Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

Prescribed List as at 1 September 2021

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made on 9 August 2021

Decision Reference:  MD-S-2021-0057

Decision Summary Title :

DS Prescribed list as of 1 September 2021

Date of Decision Summary:

 

Decision Summary Author:

Policy Principal

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

NA

Written Report

Title :

WR report PBAC 15 July 2021

Date of Written Report:

3 August 2021

Written Report Author:

Prescribing Advisor

Written Report :

Public or Exempt?

 

Public

Subject: Changes to be made to the Prescribed List (Jersey) as of 1 September 2021

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 July 2021 (unless stated otherwise) as set out in the accompanying report and supporting document.

Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee met to consider applications for changes to the Prescribed List and made the following recommendations:

 

 

1. Items to be added to the Prescribed List from 1 September 2021

1.1 Imiquimod 5% cream (250mg sachets)

1.2 Dorzolamide 20mg/mL eye drops (Eydelto brand) preservative free

1.3 Dorzolamide 20mg/mL, timolol 5mg/mL eye drops (Eylamdo brand) preservative free

1.4 Amlodipine 2.5mg tablets (additional strength)

 

2. Items to be removed from the Prescribed List (from 1 March 2022)

2.1 Dorzolamide 20mg/mL eye drops 0.2mL unit dose preservative free

2.2 Dorzolamide 20mg/mL, timolol 5mg/mL eye drops 0.2mL unit dose preservative free

 

 

3. Items not recommended for inclusion in the Prescribed List

3.1 Cavilon Durable barrier cream

 

4. Other recommendations

4.1 Liraglutide 6mg/ml solution for injection 3ml pre-filled disposable devices (Saxenda brand) – to pause recommendation to withdrawn reimbursement for this product when supplied as an adjunct to weight management pending review at next meeting

 

 

 

The above recommendations reflect current evidence and expert advice and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs and community prescribers at a proportionate cost to the Fund.

Resource Implications: The overall financial impact of the above changes is expected to be a cost reduction of around £22,000 pa.

Action required: Health Zone Manager at Customer and Local Services to issue a public notice listing amendments and notify all approved medical practitioners and approved contractors.

Signature:

 

 

Position:

Minister

 

Date Signed:

 

 

Date of Decision (If different from Date Signed):

 

Prescribed List as of 1 September 2021

RECOMMENDATIONS OF THE

PHARMACEUTICAL BENEFIT ADVISORY COMMITTEE

 

Summary

 

The Pharmaceutical Benefit Advisory Committee (PBAC) met on 15 July 2021 to consider applications for changes to the Prescribed List.

The PBAC was unanimous in its recommendations for the following changes to the Prescribed List to be implemented from 1 September 2021, unless stated otherwise.

 

1.       Items to be added to the Prescribed List from 1 September 2021

1.1 Imiquimod 5% cream (250mg sachets)

1.2 Dorzolamide 20mg/mL eye drops (Eydelto brand) preservative free

1.3 Dorzolamide 20mg/mL, timolol 5mg/mL eye drops (Eylamdo brand) preservative free

1.4 Amlodipine 2.5mg tablets (additional strength)

 

2.       Items to be removed from the Prescribed List (from 1 March 2022)

2.1   Dorzolamide 20mg/mL eye drops 0.2mL unit dose preservative free

2.2   Dorzolamide 20mg/mL, timolol 5mg/mL eye drops 0.2mL unit dose preservative free

 

 

  1. Items not recommended for inclusion in the Prescribed List
    1.    Cavilon Durable barrier cream

 

  1. Other recommendations
    1.    Liraglutide 6mg/ml solution for injection 3ml pre-filled disposable devices (Saxenda brand) – to pause recommendation to withdrawn reimbursement for this product when supplied as an adjunct to weight management pending review at next meeting

1

 


 


 

 

Mrs Alison Creed

PBAC Chair

3 August 2021

 


Recommendations

 

  1. Items to be added to the Prescribed List (from 1 September 2021)
    1.    Imiquimod 5% cream (250mg sachets)

Imiquimod cream is licensed for the treatment of external genital and perianal warts and was recommended for addition to the Prescribed List for this indication. It is also licensed for other indications including treatment of superficial basal cell carcinoma and actinic keratosis.

In the treatment of warts, imiquimod offers an effective alternative to podophyllotoxin which is also included in the List. Based on prescribing rates in England, the use of imiquimod is expected to be low with an anticipated cost impact of less than £3,000 pa.

 

 

1.2 Dorzolamide 20mg/mL eye drops (Eydelto brand) – preservative free

1.3 Dorzolamide 20mg/mL, timolol 5mg/mL eye drops (Eylamdo brand) – preservative free

Dorzolamide eye drops, with and without timolol, are used to treat raised pressure in the eye. Products containing preservatives and without preservatives are already included in the Prescribed List; the latter is presented as single dose units. Two new products, Eydelto and Eylamdo, are preservative free products containing dorzolamide/timolol but at a lower cost than the single dose units. Switching from single dose units to these 2 new products could reduce total annual expenditure by up to £26,000, based on current levels of prescribing.  

 

1.4   Amlodipine 2.5mg tablets (additional strength)

Amlodipine is used in the prevention of angina and to treat high blood pressure. Two strengths of amlodipine are included in the Prescribed List (5mg, 10mg) but a 2.5mg tablet is also available. Few patients need this strength but addition of the 2.5mg tablet to the List will remove the need for them to break a 5mg tablet.

 

 

  1. Items to be removed from the Prescribed List (from 1 March 2022)

 

The following products are recommended for removal from the List, to be replaced by items 1.2 and 1.3 listed above.

 

2.1   Dorzolamide 20mg/mL unit dose eye drops preservative free

2.2 Dorzolamide 20mg/mL, timolol 5mg/mL unit dose eye drops preservative free

 

 

  1. Items not recommended for inclusion in the Prescribed List

 

3.1  Cavilon Durable barrier cream

Cavilon Durable barrier cream is often requested and purchased by people requiring a barrier cream to protect the skin, for example, from contact with urine. It is one of a range of products used in the management of continence that are not currently included in the Prescribed List. PBAC members recommended that clarity is sought on the continence pathway and the role this product might play as one of a number of products that support this and similar conditions.

 

  1. Other recommendations

 

4.1   Liraglutide 6mg/ml solution for injection 3ml pre-filled disposable devices (Saxenda brand) – licence extension as adjunct to weight management

1

 


PBAC has received a few responses to its previous recommendation to remove liraglutide (Saxenda) brand from the Prescribed List and recommends that the decision should be revisited at the next meeting.


 

SUPPORTING DOCUMENT: CHANGES TO THE PRESCRIBED LIST AS OF 1 September 2021

 

 

 

Estimated cost impact of changes to the Prescribed List

 

Financial impact

 

The overall financial impact of the above changes is expected to be a decrease in net annual expenditure of around £22,000.    

 

 

Product

Change to Prescribed List

Estimated annual cost impact

  1. Imiquimod cream

Addition

£3,000

  1. Dorzolamide eye drops preservative free

Addition (remove single dose units)

 

-£26,000

  1. Dorzolamide/timolol eye drops preservative free
  1. Amlodipine 2.5mg tablets

Addition

£1,000

 

1

 

Back to top
rating button